Selected research
Industry Research
Colorectal Cancer Drugs Industry Research Report 2026
Market perspective
The global Colorectal Cancer Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Colorectal Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Colorectal Cancer Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Colorectal Cancer Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Colorectal Cancer Drugs include Sanofi, Merck & Co., Inc., Roch, Bayer, Amgen, Vaccinogen, Taiho Pharmaceutical, Sumitomo Dainippon and Regeneron, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Colorectal Cancer Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Colorectal Cancer Drugs Market by Company
Sanofi
Merck & Co., Inc.
Roch
Bayer
Amgen
Vaccinogen
Taiho Pharmaceutical
Sumitomo Dainippon
Regeneron
Mologen
Hutchison MediPharma
Elli Lilly
Bristol-Myers Squibb
Boehringer Ingelheim
Array BioPharma
AB Science
Colorectal Cancer Drugs Segment by Type
BRAF or MEK Inhibitors
Epidermal Growth Factor Receptor (EGFR) Inhibitors
Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors
Tyrosine Kinase (TKI) Inhibitors
Immunomodulators
Vascular Endothelial Growth Factor (VEGF) Inhibitors
Colorectal Cancer Drugs Segment by Application
Radiotherapy
Chemotherapy
Colorectal Cancer Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Colorectal Cancer Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Colorectal Cancer Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Colorectal Cancer Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Colorectal Cancer Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Colorectal Cancer Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Colorectal Cancer Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- BRAF or MEK Inhibitors
- Epidermal Growth Factor Receptor (EGFR) Inhibitors
- Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors
- Tyrosine Kinase (TKI) Inhibitors
- Immunomodulators
- Vascular Endothelial Growth Factor (VEGF) Inhibitors
Applications
- Radiotherapy
- Chemotherapy
Companies covered
- Sanofi
- Merck & Co., Inc.
- Roch
- Bayer
- Amgen
- Vaccinogen
- Taiho Pharmaceutical
- Sumitomo Dainippon
- Regeneron
- Mologen
- Hutchison MediPharma
- Elli Lilly
- Bristol-Myers Squibb
- Boehringer Ingelheim
- Array BioPharma
- AB Science
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Colorectal Cancer Drugs Market Size (2021-2032)
- 2.2.2 Global Colorectal Cancer Drugs Sales (2021-2032)
- 2.2.3 Global Colorectal Cancer Drugs Market Average Price (2021-2032)
- 2.3 Colorectal Cancer Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 BRAF or MEK Inhibitors
- 2.3.3 Epidermal Growth Factor Receptor (EGFR) Inhibitors
- 2.3.4 Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors
- 2.3.5 Tyrosine Kinase (TKI) Inhibitors
- 2.3.6 Immunomodulators
- 2.3.7 Vascular Endothelial Growth Factor (VEGF) Inhibitors
- 2.4 Colorectal Cancer Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Radiotherapy
- 2.4.3 Chemotherapy
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Colorectal Cancer Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Colorectal Cancer Drugs Sales (units) of Manufacturers (2021-2026)
- 3.3 Global Colorectal Cancer Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Colorectal Cancer Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Colorectal Cancer Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Colorectal Cancer Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Colorectal Cancer Drugs, Product Type & Application
- 3.8 Global Manufacturers of Colorectal Cancer Drugs, Established Date
- 3.9 Global Colorectal Cancer Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Sanofi
- 4.1.1 Sanofi Company Information
- 4.1.2 Sanofi Business Overview
- 4.1.3 Sanofi Colorectal Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Sanofi Colorectal Cancer Drugs Product Portfolio
- 4.1.5 Sanofi Recent Developments
- 4.2 Merck & Co., Inc.
- 4.2.1 Merck & Co., Inc. Company Information
- 4.2.2 Merck & Co., Inc. Business Overview
- 4.2.3 Merck & Co., Inc. Colorectal Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Merck & Co., Inc. Colorectal Cancer Drugs Product Portfolio
- 4.2.5 Merck & Co., Inc. Recent Developments
- 4.3 Roch
- 4.3.1 Roch Company Information
- 4.3.2 Roch Business Overview
- 4.3.3 Roch Colorectal Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Roch Colorectal Cancer Drugs Product Portfolio
- 4.3.5 Roch Recent Developments
- 4.4 Bayer
- 4.4.1 Bayer Company Information
- 4.4.2 Bayer Business Overview
- 4.4.3 Bayer Colorectal Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Bayer Colorectal Cancer Drugs Product Portfolio
- 4.4.5 Bayer Recent Developments
- 4.5 Amgen
- 4.5.1 Amgen Company Information
- 4.5.2 Amgen Business Overview
- 4.5.3 Amgen Colorectal Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Amgen Colorectal Cancer Drugs Product Portfolio
- 4.5.5 Amgen Recent Developments
- 4.6 Vaccinogen
- 4.6.1 Vaccinogen Company Information
- 4.6.2 Vaccinogen Business Overview
- 4.6.3 Vaccinogen Colorectal Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Vaccinogen Colorectal Cancer Drugs Product Portfolio
- 4.6.5 Vaccinogen Recent Developments
- 4.7 Taiho Pharmaceutical
- 4.7.1 Taiho Pharmaceutical Company Information
- 4.7.2 Taiho Pharmaceutical Business Overview
- 4.7.3 Taiho Pharmaceutical Colorectal Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Taiho Pharmaceutical Colorectal Cancer Drugs Product Portfolio
- 4.7.5 Taiho Pharmaceutical Recent Developments
- 4.8 Sumitomo Dainippon
- 4.8.1 Sumitomo Dainippon Company Information
- 4.8.2 Sumitomo Dainippon Business Overview
- 4.8.3 Sumitomo Dainippon Colorectal Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Sumitomo Dainippon Colorectal Cancer Drugs Product Portfolio
- 4.8.5 Sumitomo Dainippon Recent Developments
- 4.9 Regeneron
- 4.9.1 Regeneron Company Information
- 4.9.2 Regeneron Business Overview
- 4.9.3 Regeneron Colorectal Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Regeneron Colorectal Cancer Drugs Product Portfolio
- 4.9.5 Regeneron Recent Developments
- 4.10 Mologen
- 4.10.1 Mologen Company Information
- 4.10.2 Mologen Business Overview
- 4.10.3 Mologen Colorectal Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Mologen Colorectal Cancer Drugs Product Portfolio
- 4.10.5 Mologen Recent Developments
- 4.11 Hutchison MediPharma
- 4.11.1 Hutchison MediPharma Company Information
- 4.11.2 Hutchison MediPharma Business Overview
- 4.11.3 Hutchison MediPharma Colorectal Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Hutchison MediPharma Colorectal Cancer Drugs Product Portfolio
- 4.11.5 Hutchison MediPharma Recent Developments
- 4.12 Elli Lilly
- 4.12.1 Elli Lilly Company Information
- 4.12.2 Elli Lilly Business Overview
- 4.12.3 Elli Lilly Colorectal Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Elli Lilly Colorectal Cancer Drugs Product Portfolio
- 4.12.5 Elli Lilly Recent Developments
- 4.13 Bristol-Myers Squibb
- 4.13.1 Bristol-Myers Squibb Company Information
- 4.13.2 Bristol-Myers Squibb Business Overview
- 4.13.3 Bristol-Myers Squibb Colorectal Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Bristol-Myers Squibb Colorectal Cancer Drugs Product Portfolio
- 4.13.5 Bristol-Myers Squibb Recent Developments
- 4.14 Boehringer Ingelheim
- 4.14.1 Boehringer Ingelheim Company Information
- 4.14.2 Boehringer Ingelheim Business Overview
- 4.14.3 Boehringer Ingelheim Colorectal Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Boehringer Ingelheim Colorectal Cancer Drugs Product Portfolio
- 4.14.5 Boehringer Ingelheim Recent Developments
- 4.15 Array BioPharma
- 4.15.1 Array BioPharma Company Information
- 4.15.2 Array BioPharma Business Overview
- 4.15.3 Array BioPharma Colorectal Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Array BioPharma Colorectal Cancer Drugs Product Portfolio
- 4.15.5 Array BioPharma Recent Developments
- 4.16 AB Science
- 4.16.1 AB Science Company Information
- 4.16.2 AB Science Business Overview
- 4.16.3 AB Science Colorectal Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 AB Science Colorectal Cancer Drugs Product Portfolio
- 4.16.5 AB Science Recent Developments
5 Global Colorectal Cancer Drugs Market Scenario by Region
- 5.1 Global Colorectal Cancer Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Colorectal Cancer Drugs Sales by Region: 2021-2032
- 5.2.1 Global Colorectal Cancer Drugs Sales by Region: 2021-2026
- 5.2.2 Global Colorectal Cancer Drugs Sales by Region: 2027-2032
- 5.3 Global Colorectal Cancer Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Colorectal Cancer Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Colorectal Cancer Drugs Revenue by Region: 2027-2032
- 5.4 North America Colorectal Cancer Drugs Market Facts & Figures by Country
- 5.4.1 North America Colorectal Cancer Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Colorectal Cancer Drugs Sales by Country (2021-2032)
- 5.4.3 North America Colorectal Cancer Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Colorectal Cancer Drugs Market Facts & Figures by Country
- 5.5.1 Europe Colorectal Cancer Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Colorectal Cancer Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Colorectal Cancer Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Colorectal Cancer Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Colorectal Cancer Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Colorectal Cancer Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Colorectal Cancer Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Colorectal Cancer Drugs Market Facts & Figures by Country
- 5.7.1 South America Colorectal Cancer Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Colorectal Cancer Drugs Sales by Country (2021-2032)
- 5.7.3 South America Colorectal Cancer Drugs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Colorectal Cancer Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Colorectal Cancer Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Colorectal Cancer Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Colorectal Cancer Drugs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Colorectal Cancer Drugs Sales by Type (2021-2032)
- 6.1.1 Global Colorectal Cancer Drugs Sales by Type (2021-2032) & (units)
- 6.1.2 Global Colorectal Cancer Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Colorectal Cancer Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Colorectal Cancer Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Colorectal Cancer Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Colorectal Cancer Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Colorectal Cancer Drugs Sales by Application (2021-2032)
- 7.1.1 Global Colorectal Cancer Drugs Sales by Application (2021-2032) & (units)
- 7.1.2 Global Colorectal Cancer Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Colorectal Cancer Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Colorectal Cancer Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Colorectal Cancer Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Colorectal Cancer Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Colorectal Cancer Drugs Value Chain Analysis
- 8.1.1 Colorectal Cancer Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Colorectal Cancer Drugs Production Mode & Process
- 8.2 Colorectal Cancer Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Colorectal Cancer Drugs Distributors
- 8.2.3 Colorectal Cancer Drugs Customers
9 Global Colorectal Cancer Drugs Analyzing Market Dynamics
- 9.1 Colorectal Cancer Drugs Industry Trends
- 9.2 Colorectal Cancer Drugs Industry Drivers
- 9.3 Colorectal Cancer Drugs Industry Opportunities and Challenges
- 9.4 Colorectal Cancer Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst